Regeneron

News

US sets aside $1.4bn for COVID as new variant emerges

The Biden administration has allocated $1.4 billion to new COVID-19 vaccines and drugs, as new SARS-CoV-2 variant BA.2.86 has started spreading in the US.

News

After earlier rejection, high-dose Eylea clears FDA

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the

News

Regeneron gets FDA blessing for CHAPLE drug Veopoz

Patients with the ultra-rare disease CHAPLE now have their first FDA-approved therapy, after the regulator approved Regeneron's pozelimab for people aged one and over with

News

Regeneron dials up in gene therapy with Decibel deal

Regeneron has agreed a $109 million deal to acquire Decibel Therapeutics and its early-stage gene therapy for a form of congenital deafness, several years after forming a

News

Apogee Therapeutics upsizes its IPO to $300m

In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics has said it expects gross proceeds of $300 mill

News

Sensorion files to start trials of deafness gene therapy

French biotech Sensorion has filed its first regulatory application to start human testing of OTOF-GT, a gene therapy for one of the most common forms of congenital deafne

US sets aside $1.4bn for COVID as new variant emerges

After earlier rejection, high-dose Eylea clears FDA

Regeneron gets FDA blessing for CHAPLE drug Veopoz

Regeneron dials up in gene therapy with Decibel deal

Apogee Therapeutics upsizes its IPO to $300m

Sensorion files to start trials of deafness gene therapy

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Regeneron

Editor's Picks